WuXi Biologics WKN: A2QJCN ISIN: KYG970081173 Forum: Aktien User: Summer.76

Bank of Communications International: Optimistic about non-cyclical value stocks in the second half of the year, the first to buy 11 shares https://m.jrj.com.cn/madapter/hk/2021/06/08170832894090.shtml

China Securities Investment: Maintain WuXi Biologics (02269) "Overweight" rating, CMO strength, competitiveness, continuous enhancement, market share expected to expand https://hk.investing.com/news/stock-market-news/article-169983

Etwas allgemeiner zur WuXi und bei Bedarf ein Fall für den Übersetzer: https://hk.appledaily.com/finance/20210603/F4LTCM4WTFB4FNIAJNRU376H4Q/ WuXi Biologics (2269) went public in June 2017. Since the shares were split into three last year, the offer price is 6.86 yuan per share after the split. Next week will be the fourth anniversary of the listing, and the closing price yesterday is 120.9 yuan. According to calculations, the stock price has risen 17 times over the past four years, and the stock price can be called a myth.  ...

Mit diesem Unternehmen kommt man jeden Tag der vorzeitigen Rente ein großes Stück näher 🤌😂

Morgen ☕😎

Gute Nachrichten 👍🏼

WUXI BIO Partner's Sotrovimab Gets EUA for Covid Treatment from US FDA http://www.aastocks.com/en/stocks/news/aafn-con/NOW.1102166/popular-news

vor dem Wochenende gibt es noch mal reichlich Bewegung 📉: Bearish block trade of WUXI BIO(02269) 81K shares at $115.9, $9.388M turnover http://www.aastocks.com/en/stocks/news/aamm-content/aat2105284874/block-traded Bearish block trade of WUXI BIO(02269) 60K shares at $118.8, $7.128M turnover http://www.aastocks.com/en/stocks/news/aamm-content/aat2105284621/block-traded Bearish block trade of WUXI BIO(02269) 93.5K shares at $115.1, $10.762M turnover http://www.aastocks.com/en/stocks/news/aamm-content/aat2105284950/block-traded

WuXi Biologics (02269 HK) gains JPMorgan Chase’s increase of 1,025,564 shares https://www.finet.hk/newscenter/news_content/60af73128ac02a2b501035fe According to the equity information of the Hong Kong Stock Exchange, WuXi Biologics (02269 HK) was acquired by JPMorgan Chase on May 24 at an average price of HK$108.6527 per share to increase its holdings of 1.025 million shares, involving approximately 111 million shares. Hong Kong dollar. After the increase, JPMorgan Chase’s latest shareholding number is 381 million shares, and the shareholding ratio has increased from 8.99% to 9.02%.

👍🏼

WuXi Biologics and OncoC4 Establish Exclusive CDMO Partnership https://finance.yahoo.com/news/wuxi-biologics-oncoc4-establish-exclusive-003000473.html ...today announced that the companies have entered into an exclusive contract development and manufacturing partnership for OncoC4's full pipeline of biologics including its late-stage project, ONC-392, a next generation CTLA-4 antibody which is under phase I clinical trials in the U.S. and China.  ...

Ja stimmt, ich bin aber voll investiert,,😉😉

Was ein klasse Unternehmen. Irgendwie traurig, dass es in Deutschland bzw. Europa so unbekannt ist 🤷‍♂️

WuXi Biologics (2269 HK) rose 6%, survey minutes revealed that this year's revenue and net profit growth rate is around 50% https://m.jrj.com.cn/madapter/hk/2021/05/25140632816219.shtml WuXi Biologics (2269 HK), which was selected as one of the top ten core potential assets of Gelonghui in 2021 "Betting on China", was significantly stronger today. It rose 6.01% to 116.4 Hong Kong dollars during the day, and its market value Approaching 490 billion Hong Kong dollars. A summary of WuXi Biologics’ research and exchanges revealed: “The company’s revenue contribution from CMO projects and the number of projects will increase significantly this year. It is conservatively estimated that there will be 6 CMO projects this year, excluding other orders that may be obtained from outside. The company’s feedback to the market is that this year’s revenue and net profit have increased by about 50% year-on-year."